Brooke C. Sikora

Guest Editor for the following articles:

Sep
2013
Vol. 32. No. 3

Noninfectious Granulomatous Dermatitides: A Review of 8 Disorders (Part 2 of 3)

Alice B. Gottlieb, PhD | Ari M. Goldminz, MD

In this review we focus on 3 of the non-infectious granulomatous dermatitides, annular elastolytic giant cell granuloma, necrobiosis lipoidica, and necrobiosis xanthogranuloma, with an overview of their clinical and histological presentations, differential diagnoses, and treatment options. The disorders we discuss are polymorphic in their clinical and histopathological presentations, follow chronic or undulating disease courses, and are typically recalcitrant to therapeutic interventions. Although the clinical history may be helpful, careful and thorough histopathological examination is required. Established treatment algorithms for these disorders are lacking, and very few randomized, placebo-controlled studies have been published. Future investigations should focus on the evaluation of larger cohorts, not only to establish treatment recommendations in randomized, placebo-controlled trials, but also to reach a greater understanding of disease pathogenesis and clinical-pathological presentation.
Semin Cutan Med Surg 32:e1-e6 © 2013 Frontline Medical Communications

MORE
Mar
2012
Vol. 31. No. 1

Menus for Managing Patients With Cutaneous T-Cell Lymphoma

Brian Poligone, MD

In the management of patients with cutaneous T-cell lymphoma (CTCL), there are numerous
distinct therapy options. Each of these therapies is discussed in terms of when to use
it, what factors limit the success of the treatment, and what to expect. A menu is defined
as a list of items from which to choose. The treatments for CTCL are presented in various
menus where they are options for a particular goal in a particular setting of CTCL. The best
recognized clinical scenarios of CTCL are those recognized by the staging system: limited
patch plaque (T1), disseminated patch plaque (T2), erythroderma (T4), and tumor (T3). Each
phase of the disease will have the menu of therapy options presented for a given goal of
management.
Semin Cutan Med Surg 31:25-32 © 2012 Published by Elsevier Inc.

MORE
Sep
2013
Vol. 32. No. 3

Noninfectious Granulomatous Dermatitides: A Review of 8 Disorders (Part 3 of 3)

Alice B. Gottlieb, PhD | Ari M. Goldminz, MD

In this review we focus on 3 of the non-infectious granulomatous dermatitides, interstitial granulomatous drug reaction, rheumatoid nodules, and cutaneous sarcoidosis, with an overview of their clinical and histological presentations, differential diagnoses, and treatment options. The disorders we discuss are polymorphic in their clinical and histopathological presentations, follow chronic or undulating disease courses, and are typically recalcitrant to therapeutic interventions. Although the clinical history may be helpful, careful and thorough histopathological examination is required. Established treatment algorithms for these disorders are lacking, and very few randomized, placebo-controlled studies have been published. Future investigations should focus on the evaluation of larger cohorts, not only to establish treatment recommendations in randomized, placebo-controlled trials, but also to reach a greater understanding of disease pathogenesis and clinical-pathological presentation.
Semin Cutan Med Surg 32:e7-e11 © 2013 Frontline Medical Communications

MORE
Sep
2013
Vol. 32. No. 3

Immunology of Atopic Dermatitis: Novel Insights into Mechanisms and Immunomodulatory Therapies

April W Armstrong, MD, MPH | Caitlin T. Harskamp, BA

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin condition that is associated with immune dysregulation and epidermal barrier dysfunction. The imbalance of the Th2 and Th1 pathways and their associated cytokines in AD presents as one facet of the pathogenic mechanisms. Changes in the T-cell populations and the associated cytokines during the acute and chronic phases of AD can cause variations in disease presentations and treatment responses. Continued discoveries in the immunopathogenesis of AD provide optimism for the development of efficacious therapeutic agents. Novel immunomodulatory
therapies include apremilast, dupilumab, IL-37, omalizumab, rituximab, mepolizumab, infliximab, allergen-specific immunotherapy, Mycobacterium vaccae, and leflunomide. These agents serve as examples of how modulation in immunopathogenesis of AD can lead to therapeutic discoveries.
Semin Cutan Med Surg 32:132-139 © 2013 Frontline Medical Communications

MORE
Mar
2012
Vol. 31. No. 1

Wound Healing Update

Laurel M Morton, MD

The management of acute and chronic wounds has drastically changed within the past 20
years. This update focuses on the most recent recommendations for acute wound care as
well as new technologies that are available for chronic wounds.
Semin Cutan Med Surg 31:33-37 © 2012 Elsevier Inc. All rights reserved.

MORE